Mochida Pharmaceutical signs agreement with U.S. company PBC Biomed for U.S. sales of ReFeel, a nerve regeneration guidance material

The story

Mochida Pharmaceutical announced that it had signed a sales partnership agreement with US-based PBC Biomed concerning the US sale of its nerve regeneration material ReFeel. The agreement is believed to include the provision of sales rights and the establishment of a local distribution structure. Further details are expected to be disclosed in due course.

At a glance

CompanyMochida Pharmaceutical announced a US sales partnership

RegionSigned an agreement covering the US market

ProductsReFeel, a nerve regeneration-promoting material

CounterpartySales partnership agreement with US-based PBC Biomed

DateThe agreement was announced on 9 October 2026

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

2/ 2 agree

All of them report the same thing.

bio.nikkeibp.co.jpNews

AgreesOpen

The NikkeiNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.